Esprit is a multicenter, randomized, placebo-controlled, double-blind study assessing the safety, pharmacodynamics, and preliminary efficacy of S-606001 as a substrate reduction therapy
The trial’s primary goal is to evaluate vipoglanstat’s effect on endometriosis-related pain during non-menstrual days
The early-stage study will test the drug’s safety, tolerability and biological effects in humans
Phase I EPRAD study of DT-9081 demonstrated a favorable safety profile
ABBV-295 produced clinically meaningful, dose-dependent weight loss over 12–13 weeks
SYNT-101 is a once-daily oral pill engineered to redirect nutrient absorption beyond the small intestine’s duodenum
UBT251 appeared to have a safe and well-tolerated profile consistent with incretin-based therapies
N17350 is the company’s first-in-class tumor-directed therapeutic, designed to harness the ELANE pathway
The Phase 1 single and multiple ascending dose study is set to begin dosing in early Q1 2026
The trial aims to assess the safety, pharmacokinetics, pharmacodynamics, and preliminary efficacy of the combination therapy
Subscribe To Our Newsletter & Stay Updated
